Bank of America Corp DE reduced its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 15.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 699,026 shares of the biopharmaceutical company's stock after selling 124,301 shares during the quarter. Bank of America Corp DE owned about 0.53% of Dynavax Technologies worth $8,927,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently bought and sold shares of DVAX. SG Americas Securities LLC purchased a new position in shares of Dynavax Technologies in the 4th quarter valued at $990,000. Palumbo Wealth Management LLC purchased a new position in Dynavax Technologies during the 4th quarter worth $275,000. Barclays PLC grew its stake in Dynavax Technologies by 137.4% during the 3rd quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company's stock worth $3,371,000 after buying an additional 175,118 shares during the last quarter. Schonfeld Strategic Advisors LLC grew its stake in Dynavax Technologies by 97.6% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 310,430 shares of the biopharmaceutical company's stock worth $3,964,000 after buying an additional 153,302 shares during the last quarter. Finally, First Trust Advisors LP purchased a new position in Dynavax Technologies during the 4th quarter worth $847,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
DVAX has been the topic of several research analyst reports. HC Wainwright restated a "buy" rating and set a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. William Blair restated an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. JMP Securities dropped their price target on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Wall Street Zen downgraded Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. Finally, The Goldman Sachs Group dropped their price target on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $24.00.
Check Out Our Latest Report on DVAX
Dynavax Technologies Stock Performance
Shares of DVAX stock traded down $0.22 on Wednesday, hitting $9.57. The company had a trading volume of 1,160,973 shares, compared to its average volume of 2,215,443. The firm has a market cap of $1.15 billion, a P/E ratio of 53.25 and a beta of 1.26. The company has a 50-day moving average price of $11.25 and a 200-day moving average price of $12.40. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a twelve month low of $9.22 and a twelve month high of $14.63.
Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.14). The company had revenue of $68.16 million during the quarter, compared to analyst estimates of $70.01 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. As a group, equities research analysts predict that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.
About Dynavax Technologies
(
Free Report)
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Articles

Before you consider Dynavax Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.
While Dynavax Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.